Introduction
Patients with elevated Troponin I (Tn-I) are frequently referred for cardiac catheterization, but the absence of obstructive coronary arterial disease leads to diagnostic questions. Cardiac MRI (cMRI) is a powerful tool for characterizing myocardial abnormalities, and the use of contrast-enhanced techniques can determine the underlying pathology.
Purpose
cMRI can define the etiology of elevated Tn-I in patients with non-obstructive disease, and may help define prognosis.
Methods
All patients with non-obstructive CAD by coronary angiography (<50% luminal stenosis) and an elevated Tn-I who were referred for contrast-enhanced cMRI were retrospectively identified for the period of 11/29/2004-6/28/ 2008. Patients were subdivided based on cMRI findings: 1)Normal, 2)Ischemic Disease, 3)Myocarditis, 4)Takotsubo, and 5)Non-Ischemic Cardiomyopathy (NICM). Clinical characteristics (age, sex), Tn-I level, and ejection fraction (EF) were reviewed, as well as survival using the social security death index.
Results
53 patients met the inclusion criteria. Twenty had normal angiograms, 33 had non-obstructive disease. Six (11%) had Normal cMRI parameters, 12(23%) had Ischemic disease, 12(23%) Myocarditis, 14(26%) Tako-Tsubo, and 9(17%) NICM. There was no significant difference in age (standard deviation (SD) in parentheses) 44.4(14.7), 56.1(7.5), 49.2(18.5), 57.0(11.8), and 54.4(15.1) respectively and Tn-I, 3.6(2.5), 26.2(48.1), 11.7(17.3), 2.6(2.1), and 2.5(2.5). The EF did vary in the groups (p < 0.05), 67.5(10.5), 59.8(14.2), 51.0(15.3), 50.6(10.8), and 39.1(8.8) respectively. Patients were followed up for 2.1 ± 1.0 years. There were 6 deaths [3 in the NICM group, 2 in myocarditis, and 1 in the normal group (P = 0.16)], Table  1 .
Conclusion
Contrast enhanced cMRI is a useful modality in differentiating the conditions causing elevated Troponin I in setting of a non-obstructive coronary angiogram. Further follow-up is needed to ascertain the prognostic significance of cMRI findings. 
